Followers | 295 |
Posts | 40918 |
Boards Moderated | 11 |
Alias Born | 08/30/2001 |
Wednesday, January 12, 2022 11:44:50 AM
January 12 2022 - 09:00AM
Business Wire
Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it will host an online business update townhall meeting with Amro Albanna, Co-Founder & CEO on Tuesday, January 18th from 2:00 to 3:00 pm ET.
The upcoming meeting will include, but is not limited to, commentary on the following topics:
A business update and upcoming milestones
A summary and discussion of revenue strategy
An overview of the acquisition strategy
The online meeting will be followed by Q&A. All investors are invited to attend, whether professional or individual.
All questions can be submitted in advance via email: aditxt@edisongroup.com.
To join the webinar, CLICK HERE Or paste the link directly into your browser:
https://edisongroup.zoom.us/webinar/register/WN_fuO3kop7RqaETiLhfzzqyA
About Aditxt™
Aditxt develops technologies focused on improving immune system health through immune monitoring and reprogramming. Aditxt’s immune monitoring technology is designed to provide a personalized, comprehensive system immune system profile. Aditxt’s immune reprogramming technology, currently preclinical, is designed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. AditxtScore™ for COVID-19 is Aditxt’s proprietary immune profile technology to equip people with information about their level of protection. For more information, please visit: www.aditxt.com and www.AditxtScore.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. All statements other than historical fact contained in this press release, including, without limitation, statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development, revenue strategy and acquisition strategy; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company, are forward-looking statements. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other essential factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made. The Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005412/en/
Media and Investor Relations Contact:
Edison Investment Research
IR@aditxt.com
PROTECT YOUR ASS-ets!!
Recent ADTX News
- Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare • PR Newswire (US) • 06/27/2024 12:36:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/14/2024 08:01:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:35:45 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 06/07/2024 09:12:12 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/29/2024 08:33:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 10:08:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:24:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 08:15:45 PM
- Evofem Biosciences Announces Financial Results for the First Quarter of 2024 • PR Newswire (US) • 05/15/2024 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:15:44 PM
- CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules • Business Wire • 05/03/2024 06:14:00 PM
- Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules • Business Wire • 05/03/2024 01:00:00 PM
- Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) • Business Wire • 04/02/2024 12:30:00 PM
- Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 • PR Newswire (US) • 03/27/2024 12:36:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:51:37 PM
- For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy • PR Newswire (US) • 03/07/2024 12:54:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/04/2024 10:27:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 10:24:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 09:01:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:01:59 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/22/2024 10:21:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:30:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:30:30 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM